These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 35958418)

  • 1. Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors.
    Han Y; Nie J; Wang DW; Ni L
    Front Cardiovasc Med; 2022; 9():931475. PubMed ID: 35958418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
    Kee HJ; Kook H
    J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
    Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
    Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.
    Evans LW; Bender A; Burnett L; Godoy L; Shen Y; Staten D; Zhou T; Angermann JE; Ferguson BS
    J Nutr Biochem; 2020 May; 79():108339. PubMed ID: 32007664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The mechanism underlying histone deacetylases regulating cardiac hypertrophy].
    Ren L; Wu XS; Li YQ
    Yi Chuan; 2020 Jun; 42(6):536-547. PubMed ID: 32694112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
    Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
    Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.
    Wang Z; Zhao YT; Zhao TC
    Exp Biol Med (Maywood); 2021 Jan; 246(2):213-225. PubMed ID: 32727215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy.
    Kee HJ; Kook H
    J Mol Cell Cardiol; 2009 Dec; 47(6):770-80. PubMed ID: 19729022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
    Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
    Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
    Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
    Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding.
    Kee HJ; Sohn IS; Nam KI; Park JE; Qian YR; Yin Z; Ahn Y; Jeong MH; Bang YJ; Kim N; Kim JK; Kim KK; Epstein JA; Kook H
    Circulation; 2006 Jan; 113(1):51-9. PubMed ID: 16380549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy.
    Verza FA; Das U; Fachin AL; Dimmock JR; Marins M
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy.
    Wang J; Yun F; Sui J; Liang W; Shen D; Zhang Q
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Potential of HDAC Inhibitors in the Treatment of Cardiac Diseases: A Short Review.
    Tiwari V; Banerjee SK
    Curr Drug Targets; 2023; 24(9):718-727. PubMed ID: 36200209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation.
    Olson EN; Backs J; McKinsey TA
    Novartis Found Symp; 2006; 274():3-12; discussion 13-9, 152-5, 272-6. PubMed ID: 17019803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting histone deacetylase in cardiac diseases.
    Lu J; Qian S; Sun Z
    Front Physiol; 2024; 15():1405569. PubMed ID: 38983721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The important role of histone deacetylases in modulating vascular physiology and arteriosclerosis.
    Zhao TC; Wang Z; Zhao TY
    Atherosclerosis; 2020 Jun; 303():36-42. PubMed ID: 32535412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
    Abend A; Kehat I
    Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of pathological cardiac hypertrophy via the MEF2-coregulator interface.
    Wei J; Joshi S; Speransky S; Crowley C; Jayathilaka N; Lei X; Wu Y; Gai D; Jain S; Hoosien M; Gao Y; Chen L; Bishopric NH
    JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.
    Gallo P; Latronico MV; Gallo P; Grimaldi S; Borgia F; Todaro M; Jones P; Gallinari P; De Francesco R; Ciliberto G; Steinkühler C; Esposito G; Condorelli G
    Cardiovasc Res; 2008 Dec; 80(3):416-24. PubMed ID: 18697792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.